The novel direct oral anticoagulants (NOACs) represent a major advance in oral
anticoagulant therapy and are replacing vitamin K antagonists as the preferred options for …

Background: We determined the 2-year long-term risk-benefit profile in patients with stroke
or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for …

Atrial fibrillation is commonly coexistent with heart failure, and the management of the heart
failure patient would be incomplete without an appreciation for atrial fibrillation …

Background: Poor quality of warfarin control (time in therapeutic range [TTR]< 65%) can lead
to increased risk of adverse events. The objective of this study was to examine the overall …

Background Warfarin is an anticoagulant indicated for patients who had undergone
mechanical heart valve (s) replacement (MHVR). In these patients, time in therapeutic range …

Purpose The purpose of this study was to determine whether surgical left atrial appendage
(LAA) exclusion performed during mitral valve surgery is associated with a reduction in …

Randomized controlled trials (RCTs) examining warfarin use for stroke prevention in atrial
fibrillation (AF) may not accurately reflect real-world populations. We aimed to determine the …

Background Warfarin is used to prevent stroke in patients with atrial fibrillation (AF). Ongoing
monitoring of International normalised ratio (INR) and time in therapeutic range (TTR) …

Patients with atrial fibrillation (AF) have an increased risk of stroke and systemic embolism.
Catheter ablation (CA) is increasingly applied for the treatment for drug‑refractory AF; …

Background Anticoagulation control in patients with atrial fibrillation (AF) has a
multidisciplinary approach although is usually managed by general practitioners (GP) or …